• Je něco špatně v tomto záznamu ?

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

RC. Ungaro, C. Yzet, P. Bossuyt, FJ. Baert, T. Vanasek, GR. D'Haens, VW. Joustra, R. Panaccione, G. Novacek, W. Reinisch, A. Armuzzi, O. Golovchenko, O. Prymak, A. Goldis, SP. Travis, X. Hébuterne, M. Ferrante, G. Rogler, M. Fumery, S. Danese, G....

. 2020 ; 159 (1) : 139-147. [pub] 20200326

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020388

Grantová podpora
K23 DK111995 NIDDK NIH HHS - United States

BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.

2nd Department of Internal Medicine University Hospital Hradec Králové Hradec Králové Czech Republic

AbbVie Inc North Chicago Illinois

Amiens University Hospital Department of Gastroenterology Amiens France

AZ Delta Roeselare Roeselare Belgium

Central Clinical Hospital of Ministry of Interior and Administration in Warsaw Warsaw Poland

Claude Huriez Hospital Lille University Lille France

Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Amsterdam The Netherlands

Department of Gastroenterology and Hepatology University Hospital Zurich Zurich Switzerland

Department of Gastroenterology Faculty of Medicine and Health Örebro University Örebro Sweden

Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology Icahn School of Medicine at Mount Sinai New York New York

Department of Internal Medicine 1 Kiel University Kiel Germany

Division of Gastroenterology and Hepatology Medical University of Vienna Vienna Austria

Gastroenterology and Clinical Nutrition Department Centre Hospitalier Universitaire of Nice University of Nice Sophia Antipolis Nice France

Grigore T Popa University of Medicine and Pharmacy Iasi Romania

Hépato Gastro Entérologie Hôpital de Brabois Nancy France

Hepato Gastroenterology Department North Hospital University of Mediterranean Marseille France

Hospital Clínico de Zaragoza IIS Aragón Zaragoza Spain

Humanitas University Istituto Clinico Humanitas Milan Italy

Icahn School of Medicine at Mount Sinai Division of Gastroenterology New York New York

Imelda Gastroenterology Clinical Research Center Department of Gastroenterology Imelda General Hospital Bonheiden Belgium

Inflammatory Bowel Disease Center Sapporo Kosei General Hospital Sapporo Japan

Inflammatory Bowel Disease Unit Fondazione Policlinico Universitario A Gemelli IRCCS Università Cattolica del Sacro Cuore Rome Italy

Inflammatory Bowel Disease Unit University of Calgary Calgary Canada

Kingsbury Hospital Cape Town South Africa

Medical Clinical Investigational Center of Medical Center Health Clinic LLC Vinnytsia Ukraine

Military Medical Academy named after S M Kirov Saint Petersburg Russian Federation

Service d'Hépato gastroentérologie et Oncologie Digestive Hôpital Haut Lévêque Bordeaux France

Skane University Hospital Lund Sweden

Translational Gastroenterology Unit Nuffield Department of Experimental Medicine University of Oxford Oxford United Kingdom

Universitatea de Medicina si Farmacie Timisoara Romania

University Hospitals Leuven Leuven Belgium

University of Medicine and Pharmacy Carol Davila Bucharest Romania

Uppsala University Hospital Uppsala Sweden

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020388
003      
CZ-PrNML
005      
20210830102103.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.gastro.2020.03.039 $2 doi
035    __
$a (PubMed)32224129
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ungaro, Ryan C $u Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York
245    10
$a Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease / $c RC. Ungaro, C. Yzet, P. Bossuyt, FJ. Baert, T. Vanasek, GR. D'Haens, VW. Joustra, R. Panaccione, G. Novacek, W. Reinisch, A. Armuzzi, O. Golovchenko, O. Prymak, A. Goldis, SP. Travis, X. Hébuterne, M. Ferrante, G. Rogler, M. Fumery, S. Danese, G. Rydzewska, B. Pariente, E. Hertervig, C. Stanciu, M. Serrero, M. Diculescu, L. Peyrin-Biroulet, D. Laharie, JP. Wright, F. Gomollón, I. Gubonina, S. Schreiber, S. Motoya, PM. Hellström, J. Halfvarson, JW. Butler, J. Petersson, F. Petralia, JF. Colombel
520    9_
$a BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.
650    _2
$a adalimumab $x aplikace a dávkování $x škodlivé účinky $7 D000068879
650    _2
$a dospělí $7 D000328
650    _2
$a antiflogistika $x aplikace a dávkování $x škodlivé účinky $7 D000893
650    _2
$a azathioprin $x aplikace a dávkování $x škodlivé účinky $7 D001379
650    _2
$a Crohnova nemoc $x diagnóza $x farmakoterapie $x imunologie $x patologie $7 D003424
650    _2
$a progrese nemoci $7 D018450
650    _2
$a kombinovaná farmakoterapie $x škodlivé účinky $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    _2
$a indukce remise $x metody $7 D012074
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a TNF-alfa $x antagonisté a inhibitory $x imunologie $7 D014409
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yzet, Clara $u Amiens University Hospital, Department of Gastroenterology, Amiens, France
700    1_
$a Bossuyt, Peter $u Imelda Gastroenterology Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium
700    1_
$a Baert, Filip J $u AZ Delta Roeselare, Roeselare, Belgium
700    1_
$a Vanasek, Thomas $u Second Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a D'Haens, Geert R $u Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
700    1_
$a Joustra, Vincent Wilhelmus $u Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
700    1_
$a Panaccione, Remo $u Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Canada
700    1_
$a Novacek, Gottfried $u Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
700    1_
$a Reinisch, Walter $u Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
700    1_
$a Armuzzi, Alessandro $u Inflammatory Bowel Disease Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy
700    1_
$a Golovchenko, Oleksandr $u Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine
700    1_
$a Prymak, Olga $u Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine
700    1_
$a Goldis, Adrian $u Universitatea de Medicina si Farmacie, Timisoara, Romania
700    1_
$a Travis, Simon P $u Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom
700    1_
$a Hébuterne, Xavier $u Gastroenterology and Clinical Nutrition Department, Centre Hospitalier Universitaire of Nice, University of Nice Sophia-Antipolis, Nice, France
700    1_
$a Ferrante, Marc $u University Hospitals Leuven, Leuven, Belgium
700    1_
$a Rogler, Gerhard $u Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
700    1_
$a Fumery, Mathurin $u Amiens University Hospital, Department of Gastroenterology, Amiens, France
700    1_
$a Danese, Silvio $u Humanitas University, Istituto Clinico Humanitas, Milan, Italy
700    1_
$a Rydzewska, Grazyna $u Central Clinical Hospital of Ministry of Interior and Administration in Warsaw, Warsaw, Poland
700    1_
$a Pariente, Benjamin $u Claude Huriez Hospital, Lille University, Lille, France
700    1_
$a Hertervig, Erik $u Skane University Hospital, Lund, Sweden
700    1_
$a Stanciu, Carol $u Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
700    1_
$a Serrero, Melanie $u Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France
700    1_
$a Diculescu, Mircea $u University of Medicine and Pharmacy "Carol Davila," Bucharest, Romania
700    1_
$a Peyrin-Biroulet, Laurent $u Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France
700    1_
$a Laharie, David $u Service d'Hépato-gastroentérologie et Oncologie Digestive, Hôpital Haut-Lévêque, Bordeaux, France
700    1_
$a Wright, John P $u Kingsbury Hospital, Cape Town, South Africa
700    1_
$a Gomollón, Fernando $u Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain
700    1_
$a Gubonina, Irina $u Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russian Federation
700    1_
$a Schreiber, Stefan $u Department of Internal Medicine I, Kiel University, Kiel, Germany
700    1_
$a Motoya, Satoshi $u Inflammatory Bowel Disease Center, Sapporo Kosei General Hospital, Sapporo, Japan
700    1_
$a Hellström, Per M $u Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Halfvarson, Jonas $u Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
700    1_
$a Butler, James W $u AbbVie, Inc, North Chicago, Illinois
700    1_
$a Petersson, Joel $u AbbVie, Inc, North Chicago, Illinois
700    1_
$a Petralia, Francesca $u Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York
700    1_
$a Colombel, Jean-Frederic $u Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu
773    0_
$w MED00001877 $t Gastroenterology $x 1528-0012 $g Roč. 159, č. 1 (2020), s. 139-147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32224129 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102103 $b ABA008
999    __
$a ok $b bmc $g 1691042 $s 1140834
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 159 $c 1 $d 139-147 $e 20200326 $i 1528-0012 $m Gastroenterology $n Gastroenterology $x MED00001877
GRA    __
$a K23 DK111995 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20210728
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace